PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC.

CourtDistrict Court, D. New Jersey
DecidedOctober 22, 2020
Docket3:17-cv-06115
StatusUnknown

This text of PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC., (D.N.J. 2020).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY ____________________________________ : : PAR PHARMACEUTICAL, INC. and : PAR STERILE PRODUCTS, LLC, : : Case No. 3:17-cv-6115-BRM-DEA Plaintiffs, : : : v. : : OPINION : QUVA PHARMA, INC., STUART : HINCHEN, PETER JENKINS, MIKE : RUTKOWSKI, DONNA KOHUT, : DAVID SHORT, STEPHEN RHOADES, : TRAVIS MCGRADY, and DAVID : HARTLEY, : : Defendants. : : ____________________________________:

MARTINOTTI, DISTRICT JUDGE Before this Court is a Motion by Plaintiffs Par Pharmaceutical, Inc. and Par Sterile Products, LLC (collectively, “Par” or “Plaintiffs”) for Partial Summary Judgment on Counts V through XIII of the First Amended Complaint. (ECF No. 477.) Defendants Peter Jenkins, Stuart Hinchen, Mike Rutkowski, Donna Kohut, David Short, Stephen Rhoades, Travis McGrady, and Mike Hartley (collectively, the “Individual Defendants”) filed an Opposition to Plaintiffs’ Motion. (ECF Nos. 483 & 484.)1 Having reviewed the submissions filed in connection with the motion and having declined to hold oral argument pursuant to Federal Rule of Civil Procedure 78(b), for the

1 Defendant Stephen Rhoades filed a separate Opposition. (ECF No. 483.) reasons set forth below and for good cause shown, Par’s Motion for Partial Summary Judgment is DENIED. I. PROCEDURAL AND FACTUAL BACKGROUND A. Par Purchases Company Founded by Jenkins and Hinchen

In 2007, Peter Jenkins (“Jenkins”) and Stuart Hinchen (“Hinchen”) co-founded JHP Pharmaceuticals, LLC (“JHP”) by purchasing an existing sterile pharmaceutical manufacturing facility in Rochester, Michigan. (ECF No. 477-1 ¶ 1; ECF No. 484-1 ¶ 1.) Jenkins was JHP’s Chief Development Officer, while Hinchen was the President and CEO. (Id. ¶¶ 2–3.) In February 2014, Par Pharmaceutical, Inc. acquired JHP for $490 million and renamed the company Par Sterile Products, LLC. (Id. ¶ 4.) Jenkins and Hinchen, as co-founders and part owners of JHP, each made over $20 million from the acquisition. (Id. ¶ 5.) They both assumed new roles at Par. (Id. ¶ 6.) B. Par and the Individual Defendants Execute Non-Disclosure Contracts In June 2014, both Jenkins and Hinchen left Par and entered into a “Separation Agreement and Release.” (Id. ¶¶ 7, 15.) As part of the agreement, Jenkins and Hinchen promised to not “use,

communicate, disclose or disseminate any Confidential Information in any matter whatsoever.” (Id. ¶¶ 8, 16.) The term “Confidential Information” was defined as: “[A]ll information, data, agreements, documents, reports, ‘know-how’, interpretations, plans, studies, forecasts, projections and records (whether in written form, electronically stored or otherwise) containing or otherwise reflecting information concerning” Par. (Id. ¶¶ 9, 27.) Additionally, Jenkins and Hinchen agreed to return all Par property, which included “documents, records, and other data,” to Par. (Id. ¶¶ 11, 19.) Similar to Jenkins and Hinchen, the other Individual Defendants each held senior positions at Par and made similar promises regarding Par’s confidential information. In March 2015, Mike Rutkowski (“Rutkowski”), Donna Kohut (“Kohut”), David Short (“Short”), Stephen Rhoades (“Rhoades”), Travis McGrady (“McGrady”), and Mike Hartley (“Hartley”) each executed an identical Trade Secret, Non-Disclosure and Restrictive Covenant Agreement” (collectively, the “NDAs”) with Par in which they promised to not “divulge, disclose, or communicate to anyone or

any entity . . . any of Par’s Proprietary Information.” (Id. ¶¶ 26–27, 37–38, 46–47, 65–66, 74–75; ECF No. 483 ¶¶ 56-57.) The term “Proprietary Information” was defined as: “Par’s confidential and trade secret information, including formulas, formulations, processes, methods of manufacture, research and development including protocols and/or records, results, data, product pricing information, financial information, product pricing, marketing information, and the identity of customers including customer lists.” (Id. ¶¶ 28, 39, 48, 67, 76; ECF No. 483 ¶ 58.) These six Individual Defendants also promised to return all Par property, which included “all notebooks, documents, records and other data or information in whatever form and on whatever media,” to Par upon departure. (Id. ¶¶ 29, 38, 47, 66, 75; ECF No. 483 ¶ 57.) C. The Individual Defendants Quit Par

Jenkins and Hinchen incorporated QuVa in Delaware in July 2015, where Jenkins became QuVa’s Chief Development Officer and Hinchen became QuVa’s Chief Executive Officer. (Id. ¶¶ 80-82.) Rutkowski, who was Par’s Senior Vice President and General Manager of the Rochester facility, left Par in April 2017 to become QuVa’s Vice President and General Manager of the Bloomsbury, New Jersey facility. (Id. ¶¶ 23, 83.) Kohut, who was a Par consultant for facilities, left Par in 2015 to become QuVa’s Vice President of Operations. (Id. ¶¶ 33, 84.) Short, who was Par’s Senior Director of Quality Systems, left Par in October 2015 to become QuVa’s Vice President of Quality. (Id. ¶¶ 43, 85.) Rhoades, who was Par’s Manager of Sterility Assurance, left Par in October 2015 to become QuVa’s Director of Quality/Sterility Assurance. (Id. ¶¶ 53, 86; ECF No. 483 ¶¶ 53, 86.) McGrady, who was Par’s Manager of Deviations & Lot Distributions, left Par in February 2016 to become QuVa’s Director of Quality Systems. (Id. ¶¶ 62, 87.) Finally, Hartley, who was Par’s Director of Technical Services, left Par in March 2016 to become QuVa’s Director of Facility Engineering. (Id. ¶¶ 71, 88.)

D. The Individual Defendants Taking of Documents Par outlines several instances where the Individual Defendants took documents from Par that Par considered confidential. These allegations include: • Jenkins took a confidential Par spreadsheet about approval authority to QuVa and then circulated the Par document via email on QuVa’s computer network. (ECF No. 477-1 ¶ 90.)

• Hinchen took three confidential Par documents––one about the company’s strategy, one about a laboratory construction, and one about operations––to QuVa and then circulated the Par documents via email on QuVa’s computer network. (Id. ¶¶ 91–93.) • Rutkowski, while still employed as Par’s Senior Vice President and General Manager,

emailed Kohut (QuVa’s then-COO) six confidential Par documents––one with backorder data, one with operations data, three with quality/compliance measures, and one with operational information––and similarly disclosed Par confidential information to Kohut in the body of two emails. (Id. ¶¶ 94–99.) Rutkowski also downloaded ten confidential Par documents from his Par computer to hard drives he then took to QuVa. (Id. ¶¶ 100–10.)

• Kohut circulated two confidential Par documents with operational information via email on QuVa’s computer network. (Id. ¶¶ 111–12.) Kohut also downloaded 115 confidential Par documents to multiple hard drives and then took the hard drives to QuVa. (Id. ¶ 113.) Documents that Kohut stole include at least 6 confidential Par documents related to Par’s vasopressin products. (Id. ¶ 114.)

• Short, while employed by Par but also working with Jenkins and Hinchen to create QuVa, created a PowerPoint presentation outlining the structure for a sterility assurance department, and then sent the presentation from his personal email account to Jenkins. (Id. ¶ 115.)

• Rhoades took two confidential Par documents––one was Par’s confidential Aseptic Process Simulation (“APS”) Master Plan processes and the other was about gowning––to QuVa, and then circulated the Par documents via email on QuVa’s computer network. (Id. ¶¶ 119– 20.) Rhoades also downloaded 382 confidential Par documents to a hard drive and then took the hard drive to QuVa. (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Hunt v. Cromartie
526 U.S. 541 (Supreme Court, 1999)
National Reprographics, Inc. v. Strom
621 F. Supp. 2d 204 (D. New Jersey, 2009)
Ingersoll-Rand Co. v. Ciavatta
542 A.2d 879 (Supreme Court of New Jersey, 1988)
Community Hospital Group, Inc. v. More
869 A.2d 884 (Supreme Court of New Jersey, 2005)
Whitmyer Bros., Inc. v. DOYLE
274 A.2d 577 (Supreme Court of New Jersey, 1971)
Lamorte Burns & Co., Inc. v. Walters
770 A.2d 1158 (Supreme Court of New Jersey, 2001)
Curley v. Klem
298 F.3d 271 (Third Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/par-pharmaceutical-inc-v-quva-pharma-inc-njd-2020.